OakChart

Alcon Inc

ALCHealthcare·Medical Instruments & Supplies·Switzerland·Large·NYSE·Nov 11 • 8:49 AM ET

71.04-3.02 (-4.08%)
2026-11-11 14:51 CET
Market cap
35,704.33 USD m
Revenue, TTM
10,861.00 USD m
Net income, TTM
643.00 USD m
Free cash flow, TTM
1,740.00 USD m
EPS diluted, TTM
1.30
P/E
54.47
Compare

Price

ALC against its 20, 50 and 200-day averages
2050200beatmiss
65.0070.0075.002.7M5.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALCclose 71.0420-day 71.0950-day 67.92200-day 71.7171.04

18.9% under 87.64 on 26 Feb 2026. Last 15 sessions, 14.6% high to low

Profile

ALC
52-week range, 36% of the way up
61.8387.64

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.

Employees25942
IPOApr 09, 2019
Beta0.85
ATR, 14d2.07
Rel volume3.51
Short float3.83%
Insider own0.11%
Inst own51.90%

Snapshot

6 groups

Valuation

Index-
Market Cap34.25B
Enterprise Value38.09B
Income643.00M
Sales10.86B
Book/sh44.67
Cash/sh3.02
Dividend Est.0.34 (0.48%)
Dividend TTM0.36 (0.51%)
Dividend Ex-DateMay 06, 2026
Dividend Gr. 3/5Y15.62% 25.32%
Payout16.97%
Employees25942
IPOApr 09, 2019

Ratios

P/E54.47
Forward P/E18.05
PEG1.37
P/S3.15
P/B1.59
P/C23.52
P/FCF19.68
EV/EBITDA15.45
EV/Sales3.51
Quick Ratio1.30
Current Ratio2.09
Debt/Eq0.25
LT Debt/Eq0.22
Option/ShortYes / Yes

Earnings

EPS (ttm)1.30
EPS next Y3.94
EPS next Q0.93
EPS this Y13.77%
EPS next Y12.68%
EPS next 5Y13.20%
EPS past 3/5Y42.85% -
Sales past 3/5Y6.06% 8.77%
EPS Y/Y TTM-39.47%
Sales Y/Y TTM8.34%
EPS Q/Q-100.00%
Sales Q/Q8.74%
EarningsNov 10 AMC
EPS/Sales Surpr.3.54% -0.56%

Ownership

Insider Own0.11%
Insider Trans0.00%
Inst Own51.90%
Inst Trans-1.33%
ROA2.06%
ROE2.94%
ROIC2.45%
Gross Margin56.85%
Oper. Margin10.93%
Profit Margin5.92%
SMA20-0.07%
SMA504.60%
SMA200-0.94%
Trades-

Technical

Shs Outstand483.40M
Shs Float481.57M
Short Float3.83%
Short Ratio10.27
Short Interest18.45M
52W High87.64 -18.94%
52W Low61.83 14.89%
Volatility2.65% 2.05%
ATR (14)2.07
RSI (14)51.16
Beta0.85
Rel Volume3.51
Avg Volume1.80M
Volume315,469

Performance

Perf Week-8.11%
Perf Month12.76%
Perf Quarter-3.37%
Perf Half Y11.98%
Perf YTD-9.86%
Perf Year-8.17%
Perf 3Y-2.52%
Perf 5Y-12.79%
Perf 10Y-
Recom1.92
Target Price83.44
Prev Close74.06
Price71.04
Change %-4.08%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 07, 2026InitiatedBBarclaysEqual Weight$70-1.5%
Aug 13, 2026DowngradeBBNP Paribas ExaneOutperform → Neutral$79+11.2%
Feb 26, 2026UpgradeWWells FargoEqual Weight → Overweight$97+36.5%
Jan 30, 2026InitiatedWWilliam BlairMkt Perform
Jan 20, 2026UpgradeDDeutsche BankHold → Buy
Jan 09, 2026DowngradeSStifelBuy → Hold
Dec 11, 2025DowngradeBBofA SecuritiesBuy → Underperform$75+5.6%
Aug 21, 2025DowngradeJJP MorganOverweight → Neutral
May 20, 2025DowngradeDDeutsche BankBuy → Hold
May 14, 2025ReiteratedBBTIG ResearchBuy$102 → $99+39.4%

Peers

Mkt cap
TickerCompanyMkt cap
BLCOBausch + Lomb Corp7.67B
COOCooper Companies Inc12.07B
STAAStaar Surgical Co1.20B
GKOSGlaukos Corp14.08B
RXSTRxSight Inc205.45M
SGHTSight Sciences Inc600.25M
JNJJohnson & Johnson669.23B
WRBYWarby Parker Inc3.81B
HROWHarrow Inc1.15B
TARSTarsus Pharmaceuticals Inc3.64B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Duplan SergioOfficerFeb 26 '26Proposed Sale86.5415,0001,298,128Feb 26 03:55 PM
Attias LaurentOfficerFeb 26 '26Proposed Sale86.912,412209,634Feb 26 11:22 AM

Held by

AUM
TickerCompanyAUM
EQTYKovitz Core Equity ETFAUM: 1.39B
DFIVDimensional International Value ETFAUM: 22.32B
DFAIDimensional International Core Equity Market ETFAUM: 18.24B
DFICDimensional International Core Equity 2 ETFAUM: 15.39B
DFAXDimensional World ex U.S. Core Equity 2 ETFAUM: 11.94B
RUNNRunning Oak Efficient Growth ETFAUM: 426.53M
AGNGGlobal X Aging Population ETFAUM: 99.16M
DFSIDimensional International Sustainability Core 1 ETFAUM: 1.19B
YLDWWestwood Enhanced Income Opportunity ETFAUM: 43.07M

News

latest 14 of 196
  • Innovation and Product Launch Momentum Drive Alcons Third-Quarter 2026 Growth (Business Wire)
  • Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 (Business Wire)
  • FDA Approves Alcons BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes (Business Wire)
  • Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
  • Bernstein unveils top European medtech stock picks to buy for H2 (Investing.com)
  • Loading…
  • Platauro Metals Corp. - Star Project, Utah (TMX Newsfile)
  • STAAR Surgical hires former CEO to lead commercial team (MedTech Dive)
  • Barron's Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap (Barrons.com)
  • Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control (Business Wire)
  • Platauro Metals Corp. - Star Project, Utah (TMX Newsfile)
  • Mid-cap biotechs join Trumps latest round of drug pricing deals (BioPharma Dive)
  • Trump lines up MFN deals with nine mid-size pharmas on drug pricing push (Pharmaceutical Technology)
  • Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing (BeInCrypto)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-100.9100.8790.5402,7172,73217
2026Q22026-08-100.8400.7540.0002,7822,76218
2026Q12026-05-060.8500.8120.3862,6852,69619
2025Q42026-02-240.7800.7880.4412,7022,71219
2025Q32025-11-110.7900.7640.4782,5892,59719
2025Q22025-08-190.7600.7180.3542,5772,62219
2025Q12025-05-130.7300.7540.7032,4512,51117
2024Q42025-02-250.7200.7070.5702,4772,46220
2024Q32024-11-120.8100.7450.5282,4332,46321
2024Q22024-08-200.7400.7320.4492,4822,52819
2024Q12024-05-130.7800.7260.4992,4442,46319
2023Q42024-02-270.7000.6750.8662,3322,34017
2023Q32023-11-140.6600.6630.4112,3032,34613
2023Q22023-08-150.6900.6430.3412,4022,36715
2023Q12023-05-090.7000.6120.3512,3332,23614
2022Q42023-02-270.4200.421-0.1972,1552,16413

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.8901.893-1.3447,3627,404
2020FY1.0401.044-1.0866,7636,772
2021FY2.1502.1020.7628,2228,207
2022FY2.2402.2470.6788,6548,687
2023FY2.7402.7171.9629,3709,400
2024FY3.0503.0272.0469,8369,851
2025FY3.0703.0871.98010,31910,350
2026FY-3.493--11,054
2027FY-3.936--11,691
2028FY-4.453--12,394
2029FY-5.061--13,097
2030FY-5.843--14,082

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1114012,8392,7592,887
2026Q4S2026-11-1014012,8392,7592,887
2026Q4S2026-10-3014012,8392,7592,887
2026Q4S2026-10-2714012,8392,7592,887
2026Q4S2026-10-2614032,8392,7592,887
2026Q4S2026-10-2514032,8412,7592,887
2026Q4S2026-10-1214052,8412,7592,887
2026Q4S2026-10-0914052,8412,7592,887
2026Q4S2026-10-0614052,8412,7592,887
2026Q4S2026-09-2114042,8452,8232,887
2026Q4S2026-09-1814042,8462,8232,887
2026Q4S2026-08-1415042,8502,8232,905
2026Q4S2026-08-1316042,8512,8232,905
2026Q4S2026-08-1116022,8592,8232,941

Estimate history

EPS, annual0.524-0.465-1.344-1.0860.7620.6781.9622.0461.9751.3042
Period201720182019202020212022202320242025TTM
EPS, quarterly0.4490.5280.570.7030.3540.4780.4410.3860
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual679271537508683382918717945599111040110861
Period201720182019202020212022202320242025TTM
Sales, quarterly249624542502247325962614271827062823
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual488.7488.7491.7489.2490.1491.8493.2494.6487.4483.4
Period201720182019202020212022202320242025MRQ
Shares, quarterly494.5494.6494.6495.7494.4491.2487.4487.7483.4
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue10,861.0010,401.009,911.009,455.008,717.008,291.006,833.007,508.007,153.00
Cost of Goods Sold Incl. D&A4,687.004,656.004,396.004,201.003,908.003,603.003,759.003,869.003,961.00
Gross Profit6,174.005,745.005,515.005,254.004,809.004,688.003,074.003,639.003,192.00
Selling, General and Administrative Excl. Other4,987.004,381.004,126.004,037.003,651.003,710.003,264.003,436.003,388.00
Research and Development1,431.00990.00876.00828.00702.00653.00592.00619.00587.00
Other Operating Expense0.000.000.0036.00176.0069.00-176.00121.0052.00
Operating Income1,187.001,364.001,389.001,181.00982.00909.00-14.0082.00-248.00
Interest Expense209.00204.00192.00189.00134.00120.00124.00131.0024.00
Unusual Expense560.00-63.004.00142.00310.00329.00433.00273.00-
Net Income Before Taxes750.001,178.001,264.00832.00463.00418.00-635.00-332.00-300.00
Income Taxes98.00180.00238.00-142.00128.0042.00-104.00324.00-73.00
Consolidated Net Income643.00980.001,018.00974.00335.00376.00-531.00-656.00-227.00
Net Income From Continuing Operations643.00980.001,018.00974.00335.00376.00-531.00-656.00-227.00
Net Income643.00980.001,018.00974.00335.00376.00-531.00-656.00-227.00
EPS (Recurring)2.121.892.052.161.121.23-0.47-0.95-0.46
EPS (Basic, Before Extraordinaries)1.311.992.061.980.680.77-1.09-1.34-0.46
EPS (Diluted)1.301.982.051.960.680.76-1.09-1.34-0.46
EBITDA2,465.002,699.002,617.002,402.002,105.002,128.001,609.001,507.001,390.00
Non-Operating Income (Expense)332.00-45.0071.00-18.00-75.00-42.00-64.00-10.00-28.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense171.46128.79118.50130.51123.12128.4682.4983.22-
Price To Earnings Ratio56.4356.4336.1185.6258.95113.53---
Price To Sales Ratio3.053.824.264.103.875.264.773.68-
Gross Margin56.8555.2455.6555.5755.1756.5444.9948.4744.62
Operating Margin10.9313.1114.0112.4911.2710.96-0.201.09-3.47
Net Margin5.929.4210.2710.303.844.54-7.77-8.74-3.17
Shares Outstanding483.40487.40494.60493.20491.80490.10489.20491.70488.70
Market Capitalization35,704.3335,704.3341,876.2438,419.4233,596.3643,533.8632,970.2127,815.4727,618.79

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue2,823.002,706.002,718.002,614.002,596.002,473.002,502.002,454.00
Cost of Goods Sold Incl. D&A1,148.001,181.001,202.001,156.001,208.001,090.001,117.001,083.00
Gross Profit1,675.001,525.001,516.001,458.001,388.001,383.001,385.001,371.00
Selling, General and Administrative Excl. Other1,627.001,106.001,152.001,102.001,105.001,035.001,034.001,034.00
Research and Development663.00245.00273.00250.00245.00222.00232.00225.00
Other Operating Expense0.000.000.000.000.000.000.003.00
Operating Income48.00419.00364.00356.00283.00348.00351.00334.00
Interest Expense53.0052.0053.0051.0051.0049.0048.0049.00
Unusual Expense505.0059.00-19.0015.0070.0013.00-9.002.00
Net Income Before Taxes-42.00242.00266.00284.00200.00428.00356.00293.00
Income Taxes-46.0051.0047.0046.0023.0064.0065.0029.00
Consolidated Net Income0.00189.00217.00237.00176.00350.00284.00263.00
Net Income From Continuing Operations0.00189.00217.00237.00176.00350.00284.00263.00
Net Income0.00189.00217.00237.00176.00350.00284.00263.00
EPS (Recurring)0.720.470.410.500.450.720.560.53
EPS (Basic, Before Extraordinaries)0.000.390.440.480.360.710.570.53
EPS (Diluted)0.000.390.440.480.350.700.570.53
EBITDA336.00703.00741.00685.00602.00658.00660.00645.00
Non-Operating Income (Expense)468.00-66.00-64.00-6.0038.00142.0044.0010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense38.7035.7734.9862.0127.823.9528.4491.09
Price To Earnings Ratio56.4337.9237.2334.3639.0046.1036.1144.82
Price To Sales Ratio3.053.403.793.634.384.724.265.10
Gross Margin59.3356.3655.7855.7853.4755.9255.3655.87
Operating Margin1.7015.4813.3913.6210.9014.0714.0313.61
Net Margin0.006.987.989.076.7814.1511.3510.72
Shares Outstanding483.40487.70487.40491.20494.40495.70494.60494.60
Market Capitalization35,704.3336,725.5938,979.4336,852.6543,663.2946,952.3841,876.2449,364.53

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,608.001,830.001,101.00980.001,578.001,569.00856.00227.00172.00
Short Term Receivables2,170.001,935.001,982.001,887.001,707.001,561.001,593.001,546.001,664.00
Inventories2,391.002,268.002,322.002,109.001,899.001,644.001,505.001,440.001,303.00
Other Current Assets280.00276.00242.00217.00202.00213.00282.00186.00148.00
Total Current Assets6,449.006,309.005,647.005,193.005,386.004,987.004,236.003,399.003,287.00
Net Property, Plant & Equipment5,221.004,838.004,723.004,416.004,083.003,783.003,437.002,879.002,560.00
Total Investments and Advances409.00576.00148.00108.0052.0040.0059.0046.0051.00
Long-Term Note Receivable168.00121.00126.00119.00110.00117.00136.00164.00197.00
Intangible Assets18,262.0017,533.0017,986.0018,615.0017,670.0018,002.0019,136.0019,578.0020,436.00
Deferred Tax Assets458.00421.00443.00411.00409.00399.00354.00670.00526.00
Other Assets588.00549.00541.00303.00289.00272.00297.00326.00331.00
Total Assets31,555.0030,347.0029,614.0029,165.0027,999.0027,600.0027,655.0027,062.0027,388.00
Short Term Debt Incl. Current Port. of LT Debt655.00173.00216.00178.00181.00239.00322.0047.0065.00
Accounts Payable926.00773.00811.00861.00903.00876.00833.00748.00672.00
Income Tax Payable182.00104.00114.00175.00187.00149.00107.00151.00105.00
Other Current Liabilities1,286.001,228.001,339.001,524.001,201.00994.001,038.00947.00936.00
Total Current Liabilities3,049.002,278.002,480.002,738.002,472.002,258.002,300.001,893.001,778.00
Long Term Debt4,591.004,967.004,929.004,900.004,305.004,264.003,498.0089.0084.00
Provision for Risks Charges648.00611.00618.00556.00772.00823.00854.00703.00669.00
Deferred Tax Liabilities941.00724.00797.001,064.001,026.001,196.001,386.001,528.001,640.00
Other Liabilities291.00214.00166.00230.00168.00237.00314.00210.00188.00
Total Liabilities9,520.008,794.008,990.009,488.008,743.008,778.008,352.004,423.004,359.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity22,034.0021,553.0020,624.0019,677.0019,256.0018,822.0019,303.0022,639.0023,029.00
Total Shareholders Equity22,034.0021,553.0020,624.0019,677.0019,256.0018,822.0019,303.0022,639.0023,029.00
Accumulated Minority Interest1.000.000.000.000.000.000.000.000.00
Total Equity22,035.0021,553.0020,624.0019,677.0019,256.0018,822.0019,303.0022,639.0023,029.00
Total Liabilities & Stockholders Equity31,555.0030,347.0029,614.0029,165.0027,999.0027,600.0027,655.0027,062.0027,388.00
Book Value Per Share45.2143.5841.8240.0139.2938.4839.2646.3247.12
Tangible Book Value Per Share7.748.135.352.163.241.680.346.265.31
Full-Time Employees25,94225,59925,31525,17824,38923,65522,14220,38119,130
Price to Book Ratio1.661.961.911.722.221.711.441.41-
Return on Assets3.173.403.311.171.35-1.92-2.40-0.830.93
Return on Equity4.504.834.831.721.97-2.79-3.13-0.991.11
Return on Invested Capital3.683.843.811.361.60-2.30-2.88-1.001.11
Quick Ratio1.331.771.341.131.411.481.191.031.12
Current Ratio2.122.772.281.902.182.211.841.801.85

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income643.00980.001,018.00974.00335.00376.00-531.00-656.00-227.00
Depreciation1,278.001,335.001,228.001,221.001,123.001,219.001,623.001,425.001,638.00
Other Funds (Non Cash)775.00256.00107.00-403.00281.00126.00-109.00282.00-284.00
Funds from Operations2,696.002,571.002,353.001,792.001,739.001,721.00983.001,051.001,127.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-386.00-300.00-276.00-404.00-522.00-376.00-160.00-131.0013.00
Cash from Operating Activities2,310.002,271.002,077.001,388.001,217.001,345.00823.00920.001,140.00
Capital Expenditures-721.00-663.00-670.00-851.00-745.00-1,180.00-567.00-677.00-769.00
Net Assets From Acquisitions-139.00-718.00-61.00-2.00-1,151.000.000.00-283.00-239.00
Sale of Fixed Assets and Businesses5.005.000.000.000.000.006.000.00-
Purchase or Sale of Investments-215.0014.00-278.00-231.0031.00-18.00-11.00-51.000.00
Purchase of Investments-303.00-144.00-287.00-233.00-50.00-19.00-11.00-59.000.00
Sale Or Maturity of Investments88.00158.009.002.0081.001.000.008.000.00
Other Uses2.00-8.00-158.00-10.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.007.00
Cash from Investing Activities-1,067.00-1,370.00-1,167.00-1,094.00-1,865.00-1,198.00-572.00-1,011.00-1,001.00
Cash Dividends Paid-174.00-166.00-130.00-116.00-100.00-54.000.000.000.00
Change in Capital Stock-913.00-676.000.000.000.000.000.000.000.00
Repurchase of Common Pref Stock-913.00-676.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net--15.00-54.0072.00277.009.00536.003,360.00-6.00
Change in Long Term Debt---29.00639.0052.00675.003,158.000.00
Issuance of Long Term Debt---29.001,815.0052.00744.005,219.000.00
Reduction of Long Term Debt-----1,176.000.00-69.00-2,061.000.00
Net Financing Active Other Cash Flow-95.00-155.00-55.00-88.00-116.00-6.00-70.00-2,701.00-72.00
Other Financing Activities Uses-95.00-155.00-55.00-88.00-116.00-6.00-70.00-2,740.00-119.00
Cash from Financing Activities-1,268.00-1,093.00-322.00-211.00-8.00-123.00466.00659.00-78.00
Exchange Rate Effect-28.0043.00-6.0031.0061.00-6.0018.0027.00-6.00
Net Change in Cash-53.00-149.00582.00114.00-595.0018.00735.00595.0055.00
Free Cash Flow1,740.001,728.001,604.00730.00581.00645.00344.00367.00616.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow21.1225.4228.6363.0670.1973.7794.7475.22-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1,456.001,659.001,608.001,498.001,408.001,412.00
Short Term Receivables2,100.002,010.002,170.001,939.002,015.001,857.00
Inventories2,510.002,438.002,391.002,433.002,394.002,343.00
Other Current Assets558.00513.00280.00463.00489.00455.00
Total Current Assets6,624.006,620.006,449.006,333.006,306.006,067.00
Net Property, Plant & Equipment5,257.005,223.005,221.005,147.005,075.004,903.00
Total Investments and Advances768.00800.00409.00740.00763.00294.00
Intangible Assets17,529.0018,136.0018,262.0018,428.0018,376.0018,559.00
Deferred Tax Assets486.00464.00458.00477.00470.00430.00
Other Assets434.00376.00588.00399.00397.00755.00
Total Assets31,098.0031,619.0031,555.0031,524.0031,387.0031,008.00
Short Term Debt Incl. Current Port. of LT Debt651.00657.00655.00649.00157.00179.00
Accounts Payable968.00919.00926.00895.00895.00842.00
Income Tax Payable228.00208.00182.00196.00215.00127.00
Other Current Liabilities1,320.001,220.001,286.001,250.001,157.001,098.00
Total Current Liabilities3,167.003,004.003,049.002,990.002,424.002,246.00
Long Term Debt4,648.004,605.004,591.004,591.005,104.005,025.00
Provision for Risks Charges0.000.00648.000.000.000.00
Deferred Tax Liabilities841.00944.00941.00911.00857.00894.00
Other Liabilities846.00933.00291.00944.00872.00824.00
Total Liabilities9,502.009,486.009,520.009,436.009,257.008,989.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity21,595.0022,132.0022,034.0022,086.0022,114.0022,003.00
Total Shareholders Equity21,595.0022,132.0022,034.0022,086.0022,114.0022,003.00
Accumulated Minority Interest1.001.001.002.0016.0016.00
Total Equity21,596.0022,133.0022,035.0022,088.0022,130.0022,019.00
Total Liabilities & Stockholders Equity31,098.0031,619.0031,555.0031,524.0031,387.0031,008.00
Book Value Per Share44.6745.3845.2144.9644.7344.39
Tangible Book Value Per Share8.418.197.747.457.566.95
Full-Time Employees--25,942---
Price to Book Ratio1.661.671.751.671.992.18
Return on Assets2.062.623.173.383.513.70
Return on Equity2.943.714.504.824.985.23
Return on Invested Capital0.000.710.820.890.651.29
Quick Ratio1.301.391.331.301.611.66
Current Ratio2.092.202.122.122.602.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income0.00189.00217.00237.00176.00350.00
Depreciation250.00322.00377.00329.00319.00310.00
Other Funds (Non Cash)429.00182.0073.0091.00123.00-31.00
Funds from Operations679.00693.00667.00657.00618.00629.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-169.00-275.00-9.0067.00-113.00-245.00
Cash from Operating Activities510.00418.00658.00724.00505.00384.00
Capital Expenditures-140.00-191.00-201.00-189.00-133.00-140.00
Net Assets From Acquisitions0.000.000.00-139.00-11.00-568.00
Sale of Fixed Assets and Businesses0.000.000.005.000.000.00
Purchase or Sale of Investments-82.00-28.00-101.00-4.00-21.00140.00
Purchase of Investments-163.00-28.00-106.00-6.00-22.00-10.00
Sale Or Maturity of Investments81.000.005.002.001.00150.00
Other Uses0.000.001.001.000.00-10.00
Other Sources0.001.000.00---
Cash from Investing Activities-222.00-218.00-301.00-326.00-165.00-578.00
Cash Dividends Paid-174.000.000.000.00-166.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-278.00-75.00-307.00-253.00-116.000.00
Repurchase of Common Pref Stock-278.00-75.00-307.00-253.00-116.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-5.006.002.00-3.00-16.002.00
Net Financing Active Other Cash Flow-32.00-42.00-3.00-18.00-55.00-79.00
Other Financing Activities Uses-32.00-42.00-3.00-18.00-55.00-79.00
Cash from Financing Activities-510.00-133.00-329.00-296.00-372.00-96.00
Exchange Rate Effect-1.00-16.001.00-12.0028.0026.00
Net Change in Cash-223.0051.0029.0090.00-4.00-264.00
Free Cash Flow414.00279.00489.00558.00403.00278.00
Price to Free Cash Flow21.1223.1325.2226.7430.2430.76

Revenue breakdown

Consumables2024: 2.86B 2025: 3.03B
Contact Lenses2024: 2.61B 2025: 2.77B
Equipment & Other2024: 886.00M 2025: 941.00M
Implantables2024: 1.78B 2025: 1.78B
Ocular Health2024: 1.71B 2025: 1.80B
China2024: 560.00M 2025: 570.00M
Japan2024: 554.00M 2025: 609.00M
Other Countries2024: 4.13B 2025: 4.41B
Switzerland2024: 79.00M 2025: 71.00M
United States2024: 4.51B 2025: 4.66B
Surgical2024: 5.52B 2025: 5.75B
Vision Care2024: 4.31B 2025: 4.57B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.83%18.4M481.6M1.69M
2026-10-154.06%19.6M481.6M1.82M
2026-09-303.71%17.9M481.6M1.92M
2026-09-153.63%17.5M481.6M1.92M
2026-08-313.02%14.6M481.6M1.94M
2026-08-142.46%11.9M481.6M2.18M
2026-07-312.81%13.7M486.6M2.30M
2026-07-152.70%13.0M481.4M2.15M
2026-06-302.16%10.4M481.4M1.98M
2026-06-151.79%8.6M481.4M1.91M
2026-05-291.17%5.6M481.4M1.88M
2026-05-151.24%6.0M481.4M1.81M
2026-04-301.11%5.4M481.8M1.67M
2026-04-151.07%5.1M481.8M1.67M
2026-03-311.02%4.9M481.8M1.66M
2026-03-131.00%4.8M481.8M1.56M
2026-02-271.10%5.3M481.8M1.56M
2026-02-131.34%6.4M481.8M1.55M
2026-01-301.55%7.6M489.3M1.66M
2026-01-151.37%6.7M489.3M1.72M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call40.0032.0036.000.003.3450.000.000.993-0.0230.002
call42.5029.5033.700.002.9890.000.000.992-0.0230.003
call45.0027.0031.1022.102.7961060.000.991-0.0230.003
call47.5024.5028.7018.102.51411.000.000.990-0.0230.003
call50.0022.1026.0016.802.36769.000.000.989-0.0230.003
call55.0017.1021.1012.511.9164.000.000.958-0.0670.011
call57.5014.7018.6016.501.77256.000.000.952-0.0650.012
call60.0012.3016.004.901.5391640.000.945-0.0630.013
call62.5010.3013.2010.901.1996561.000.893-0.1080.022
call65.007.6011.1010.501.1795850.000.873-0.1000.025
call67.505.809.308.501.1574,1040.000.743-0.2030.039
call70.004.406.806.300.9135120.000.683-0.2040.043
call72.502.454.303.950.71536221.000.600-0.1680.047
call75.002.402.752.750.6491,0268440.477-0.1630.048
call77.501.501.951.500.6801,2581,1840.387-0.1850.047
call80.000.902.000.950.8451,9211,7560.322-0.1950.044
call82.500.151.300.620.73333.001.000.210-0.1320.035
call85.000.100.500.360.69293.0081.000.126-0.0890.025
call87.500.001.050.150.79278.0073.000.113-0.0950.023
call90.000.000.150.100.67111.004.000.046-0.0410.012
call95.000.002.150.480.8260.000.000.039-0.0430.010
call1000.002.150.000.9610.000.000.034-0.0450.009
call1050.002.150.001.0780.000.000.031-0.0470.009
call1100.002.150.001.1950.000.000.029-0.0490.008
call1150.002.100.001.3110.000.000.027-0.0500.007
call1200.002.150.001.4070.000.000.025-0.0510.007
put40.000.002.150.001.6280.000.00-0.007-0.0200.002
put42.500.002.150.001.4820.000.00-0.008-0.0200.003
put45.000.002.150.251.33810.000.00-0.009-0.0190.003
put47.500.002.150.271.20725.000.00-0.009-0.0190.003
put50.000.000.050.251.3702370.00-0.035-0.0650.009
put55.000.050.500.050.94141024.00-0.022-0.0310.006
put57.500.002.150.080.9833430.00-0.047-0.0600.012
put60.000.002.400.600.8411,0300.00-0.055-0.0570.013
put62.500.152.450.300.8933,499322-0.108-0.1020.023
put65.000.000.600.500.741918601-0.127-0.0940.025
put67.500.403.001.040.988883933-0.256-0.1960.039
put70.001.253.601.500.8911,4561,570-0.322-0.1970.044
put72.501.653.602.510.6671,6411,665-0.400-0.1610.047
put75.003.203.603.400.6451,2661,223-0.522-0.1550.048
put77.504.806.905.001.01825.0015.00-0.613-0.1780.047
put80.006.208.905.801.08812.000.00-0.678-0.1870.044
put82.508.2010.200.000.9650.000.00-0.764-0.1510.037
put85.0010.6012.5012.371.0831.001.00-0.873-0.0800.025
put87.5012.5015.300.001.2860.000.00-0.886-0.0850.023
put90.0014.9018.000.001.4830.000.00-0.954-0.0320.012
put95.0019.9023.000.001.6770.000.00-0.961-0.0340.010
put10023.9028.000.001.8320.000.00-0.965-0.0350.009
put10528.8033.000.002.0110.000.00-0.969-0.0370.009
put11033.8038.000.002.2250.000.00-0.971-0.0380.008
put11538.8043.000.002.3810.000.00-0.973-0.0380.008
put12043.8048.000.002.5270.000.00-0.975-0.0390.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-08-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-05-15SDSpecialized Disclosure ReportSEC
2026-05-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-02SEC
2026-02-26144Filing for proposed sale of securities under Rule 144.SEC
2026-02-26144Filing for proposed sale of securities under Rule 144.SEC
2026-02-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC
2026-02-2420-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-02-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC
2026-01-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-06SEC
2025-12-09DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-11-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-30SEC
2025-11-04DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-30SEC
2025-08-05DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-08-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-08-05SEC
2025-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-05-28SEC
2025-05-28SDSpecialized Disclosure ReportSEC
2025-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-03-31SEC
2025-04-23SCHEDULE 13G/ASEC
2025-04-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-04-04SEC
2025-03-24DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-03-03144Filing for proposed sale of securities under Rule 144.SEC
2025-02-28144Filing for proposed sale of securities under Rule 144.SEC
2025-02-27144Filing for proposed sale of securities under Rule 144.SEC
2025-02-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-31SEC
2025-02-2520-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2024-12-31SEC
2025-02-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-31SEC
2024-11-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-09-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.03%
NORGES BANK2.25%
Invesco Ltd.2.13%
Bank of New York Mellon Corp2.10%
AKO CAPITAL LLP1.99%
Aristotle Capital Management, LLC1.88%
Zurcher Kantonalbank1.66%
FMR LLC1.57%
UBS Group AG1.57%
Amundi1.35%

Funds

Fund% owned
Fidelity Series Large Cap Stock Fund0.43%
Fidelity International Index Fund0.41%
Strategic Advisers Fidelity U.S. Total Stock Fund0.33%
Fidelity Growth and Income Portfolio0.28%
Fidelity Series Overseas Fund0.22%
Fidelity Series Global ex U.S. Index Fund0.20%
BNY Mellon Dynamic Value Fund0.19%
BNY Mellon International Stock Fund0.19%
ClearBridge International Growth Fund0.16%
Fidelity Large Cap Stock Fund0.16%

OakChart. ALC. Cached 15 minutes.